
Blackstone Closes Record $6.3B Life Sciences Fund
Blackstone has closed its oversubscribed Blackstone Life Sciences VI (BXLS VI) fund at a $6.3 billion hard cap, making it the firm’s largest life sciences-focused fund to date and nearly 40% larger than its predecessor.
Since launching its dedicated life sciences platform in 2018, Blackstone has grown BXLS to approximately $15 billion in assets under management as of the fourth quarter of 2025. The platform has supported the development and commercialization of therapies and devices, including LEQVIO, AMVUTTRA, IMBRUVICA and the MiniMed Flex system.
“Our partnerships with global leaders have produced 34 regulatory approvals of innovative medicines and devices,” said Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences. “This track record highlights how we work successfully with industry trailblazers to help bring their most important products to patients around the world.”
Over the past 12 months, BXLS has committed nearly $2 billion in new investments, underscoring continued deployment activity.